Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-03-29
Based on 1185 first isolates · PHC-N · Febrile UTI / pyelonephritis · 2025-03-30 → 2026-03-29
Health centre North
Per-organism detail: PHC-N urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
piperacillin-tazobactam 81 % (79 %–83 %)
Keep for severe or hospital-onset infections.
Not covered: Enterococcus faecalis (9 %), Staphylococcus aureus (4 %), Staphylococcus saprophyticus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
88 %
n = 92
nitrofurantoin NIT
trend · Escherichia coli not for this site
82 %
87 %
n = 92
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
86 %
n = 92
ciprofloxacin CIP
trend · Escherichia coli
78 %
83 %
n = 92
mecillinam MEC
trend · Escherichia coli not for this site
77 %
77 %
n = 92
ceftriaxone CRO
trend · Escherichia coli
75 %
80 %
n = 92
trimethoprim TMP
trend · Escherichia coli not for this site
73 %
77 %
n = 92
72 %
74 %
n = 92
50 %
55 %
n = 92
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
10 %
n = 92
5 %
7 %
n = 92
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
2 %
n = 92

Most likely organisms for this profile

Escherichia coli
51 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
9 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
6 %
Staphylococcus aureus
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.